Christopher Bishop

Dr. Christopher Bishop

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
DLDavid Lindenbach
David Lindenbach
CBChristopher Bishop
Christopher Bishop

23 March 2009 in Synapse
Verified
Journal Article
Closed access
PDF file
KEKaren L. Eskow
Karen L. Eskow
KDKristin B. Dupre
Kristin B. Dupre
CBChristopher J. Barnum
Christopher J. Barnum
SDSando O. Dickinson
Sando O. Dickinson
JPJohn Y. Park
John Y. Park
CBChristopher Bishop
Christopher Bishop

1 January 2011 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
KJKaren L. Eskow Jaunarajs
Karen L. Eskow Jaunarajs
MAMariana Angoa-Perez
Mariana Angoa-Perez
DKDonald M. Kuhn
Donald M. Kuhn
CBChristopher Bishop
Christopher Bishop

1 June 2011 in Experimental Neurology
Verified
Journal Article
Closed access
KDKristin B. Dupre
Kristin B. Dupre
COCorinne Y. Ostock
Corinne Y. Ostock
KJKaren L. Eskow Jaunarajs
Karen L. Eskow Jaunarajs
TBThomas Button
Thomas Button
LSLisa M. Savage
Lisa M. Savage
CBChristopher Bishop
Christopher Bishop

1 September 2008 in Neuroscience
Verified
Journal Article
Closed access
CBC.J. Barnum
C.J. Barnum
KEK.L. Eskow
K.L. Eskow
KDK. Dupre
K. Dupre
PBP. Blandino
P. Blandino
TDTerrence Deak
Terrence Deak
CBChristopher Bishop
Christopher Bishop

1 October 2010 in Behavioural Pharmacology
Verified
Journal Article
Closed access
KJKaren L. Eskow Jaunarajs
Karen L. Eskow Jaunarajs
KDKristin B. Dupre
Kristin B. Dupre
COCorinne Y. Ostock
Corinne Y. Ostock
TBThomas Button
Thomas Button
TDTerrence Deak
Terrence Deak
CBChristopher Bishop
Christopher Bishop
Depression and anxiety are the prevalent nonmotor symptoms that worsen quality of life for Parkinson's disease (PD) patients. Although dopamine (DA) cell loss is a commonly proposed mechanism, the reported efficacy of DA replacement therapy with L-DOPA on affective symptoms is inconsistent. To delineate the effects of DA denervation and chronic L-DOPA treatment on affective behaviors, male Sprague–Dawley rats received unilateral 6-hydroxydopamine or sham lesions and were treated daily with L-DOPA (12 mg/kg+benserazide, 15 mg/kg, subcutaneously) or vehicle (0.9% NaCl, 0.1% ascorbic acid) for 28 days before commencing investigations into anxiety (locomotor chambers, social interaction) and depression-like behaviors (forced swim test) during the OFF phase of L-DOPA. One hour after the final treatments, rats were killed and striatum, prefrontal cortex, hippocampus, and amygdala were analyzed through high-performance liquid chromatography for monoamine levels. In locomotor chambers and social interaction, DA lesions exerted mild anxiogenic effects. Surprisingly, chronic L-DOPA treatment did not improve these effects. Although DA lesion reduced climbing behaviors on day 2 of exposure to the forced swim test, chronic L-DOPA treatment did not reverse these effects. Neurochemically, L-DOPA treatment in hemiparkinsonian rats reduced norepinephrine levels in the prefrontal cortex, striatum, and hippocampus. Collectively, these data suggest that chronic L-DOPA therapy in severely DA-lesioned rats does not improve nonmotor symptoms and may impair nondopaminergic processes, indicating that long-term L-DOPA therapy does not exert necessary neuroplastic changes for improving affect.